Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
George Washington University Medical Faculty Associates
mi
from
Washington,
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
George Washington University Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
UCSF Helen Diller Comprehensive Cancer Center
mi
from
San Francisco, CA
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
UCSF Helen Diller Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
Phase II, Single Center, Single Arm, Open Label Investigation of Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
Phase II, Single Center, Single Arm, Open Label Investigation of Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis
Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Center of Wake Forset University
mi
from
Winston-Salem, NC
Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis
Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Center of Wake Forset University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.
Status: Enrolling
Updated:  12/31/1969
Medicine Invention Design, Inc. (MIDI) - c/o - MIDINC Clinical Investigator Working Site
mi
from
Gaithersburg, MD
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.
Status: Enrolling
Updated: 12/31/1969
Medicine Invention Design, Inc. (MIDI) - c/o - MIDINC Clinical Investigator Working Site
mi
from
Gaithersburg, MD
Click here to add this to my saved trials
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.
Status: Enrolling
Updated:  12/31/1969
MIDI Clinical Trial Sites -c/o- Dr. Han Xu - Physicians / Investigators / Laboratories assigned by CRO
mi
from
Gaithersburg, MD
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.
Status: Enrolling
Updated: 12/31/1969
MIDI Clinical Trial Sites -c/o- Dr. Han Xu - Physicians / Investigators / Laboratories assigned by CRO
mi
from
Gaithersburg, MD
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Urology Centers of Alabama
mi
from
Homewood, AL
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urology Centers of Alabama
mi
from
Homewood, AL
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists-East
mi
from
West Palm Beach, FL
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists-East
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Ingalls Memorial Hospital
mi
from
Harvey, IL
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana Cancer Pavilion
mi
from
Indianapolis, IN
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana Cancer Pavilion
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Urology Cancer Center, PC
mi
from
Omaha, NE
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urology Cancer Center, PC
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care
mi
from
Cincinnati, OH
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Urology Associates
mi
from
Nashville, TN
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urology Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Southwestern Medical Center at Dallas
mi
from
Dallas, TX
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Prostate Oncology Specialists, Inc.
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Associated Medical Professionals of NY
mi
from
Syracuse, NY
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Associated Medical Professionals of NY
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Oregon Urology Institute
mi
from
Springfield, OR
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Oregon Urology Institute
mi
from
Springfield, OR
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Urological Associates of Lancaster
mi
from
Lancaster, PA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Urological Associates of Lancaster
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Garden State Urology
mi
from
Morristown, NJ
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Garden State Urology
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Sharp Memorial Hospital
mi
from
San Diego, CA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists, PC
mi
from
Tualatin, OR
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Univ of Pittsburgh Cancer Inst. (UPCI)
mi
from
Pittsburgh, PA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Univ of Pittsburgh Cancer Inst. (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
US Oncology
mi
from
The Woodlands, TX
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
US Oncology
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists North
mi
from
Saint Petersburg, FL
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists North
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute (SCRI)
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Fort Worth, TX
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University of Washington/Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Relationship of Mitochondrial Enzymes With Cancer Related Fatigue
Relationship of Mitochondrial Enzymes With Cancer Related Fatigue
Status: Enrolling
Updated:  12/31/1969
University of Florida
mi
from
Gainesville, FL
Relationship of Mitochondrial Enzymes With Cancer Related Fatigue
Relationship of Mitochondrial Enzymes With Cancer Related Fatigue
Status: Enrolling
Updated: 12/31/1969
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Enrolling
Updated:  12/31/1969
St. Jude Medical Center
mi
from
Fullerton, CA
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Enrolling
Updated: 12/31/1969
St. Jude Medical Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Enrolling
Updated:  12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Status: Enrolling
Updated: 12/31/1969
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials